NSRX — Nasus Pharma Ltd
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 2029039 ·
Last close
$3.03
Market Cap
$35.48M
52W High
$3.68
52W Low
$2.60
ADV30
15,447
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 5,004,000 | 1,237,000 | 2,236,000 |
| Jun 2025 | — | — | — | — | 639,000 | 203,000 | 4,953,000 |
| Dec 2024 | — | — | — | — | 717,000 | 284,000 | 3,929,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-18,520,000
Inventory
—
Receivables
—
ST Investments
$3,049,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -4,904,000 | -5,856,000 | 5,004,000 | 2,236,000 | — | -4,918,000 |
| Dec 2024 | 0 | -1,078,000 | -1,532,000 | 717,000 | 3,929,000 | — | -665,000 |
| Dec 2023 | 0 | -1,147,000 | -1,051,000 | 444,000 | 4,241,000 | — | -1,029,000 |
| Dec 2022 | 0 | -2,042,000 | -1,711,000 | 417,000 | 3,202,000 | — | -1,211,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ENLV | Enlivex Ltd. | $35.18M | $2.09 | — |
| IXHL | Incannex Healthcare Inc. | $35.18M | $2.94 | — |
| VERU | VERU INC. | $35.95M | $2.24 | — |
| BETRF | BetterLife Pharma Inc. | $34.07M | $0.21 | — |
| GRCE | Grace Therapeutics, Inc. | $33.85M | $2.08 | — |
News headlines (Yahoo Finance, 1h cache)
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
2026-07-28 11:30 · Yahoo
OTC Markets Life Sciences Investor Forum: Dan Teleman, CEO, and Eyal Rubin, SVP and CFO, of Nasus Pharma with Zacks SCR's John Vandermosten, CFA
2026-07-07 10:42 · Yahoo
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
2026-06-26 12:35 · Yahoo
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
2026-06-23 12:35 · Yahoo
NSRX: NS002 June KOL Event
2026-06-22 12:04 · Yahoo
Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum
2026-06-22 12:00 · Yahoo
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
2026-06-09 12:00 · Yahoo
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
2026-06-01 12:00 · Yahoo
NSRX: Initiating Coverage – Sniffing Out a Better Solution
2026-05-22 07:00 · Yahoo
Nasus Pharma to Participate in Upcoming Investor Conferences
2026-05-01 13:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.